Forschung & Innovation
Publikationen
Nonmetastatic pancreatic cancer
PMU Autor*innen
Gerd Fastner, Andrea Vaszi, Wolfgang Iglseder, Peter Kopp, Josef Holzinger, Adam Dinnewitzer, Gabriel Rinnerthaler, Simon Peter Gampenrieder, Klaus Emmanuel, Richard Greil, Felix Sedlmayer, Franz Zehentmayr
Alle Autor*innen
Sebastian Bachmayer, Gerd Fastner, Andrea Vaszi, Wolfgang Iglseder, Peter Kopp, Josef Holzinger, Adam Dinnewitzer, Gabriel Rinnerthaler, Simon Peter Gampenrieder, Klaus Emmanuel, Richard Greil, Felix Sedlmayer, Franz Zehentmayr
Fachzeitschrift
STRAHLENTHERAPIE UND ONKOLOGIE
Kurzfassung
The role of radiotherapy (RT) for nonmetastatic pancreatic cancer is still a matter of debate since randomized control trials have shown inconsistent results. The current retrospective single-institution study includes both resected and unresected patients with nonmetastasized pancreatic cancer. The aim is to analyze overall survival (OS) after irradiation combined with induction chemotherapy.Of the 73 patients with nonmetastatic pancreatic cancer eligible for the present analysis, 42 (58%) patients had adjuvant chemoradiotherapy (CRT), while 31 (42%) received CRT as primary treatment. In all, 65 (89%) had chemotherapy at any time before, during, or after RT, and 39 (53%) received concomitant CRT. The median total dose was 50Gy (range 12-77Gy), while 61 (84%) patients received > 40Gy.With a median follow-up of 22 months (range 1.2-179.8 months), 14 (19%) are still alive and 59 (81%) of the patients have died, whereby 51 (70%) were cancer-related deaths. Median OS and the 2aEuroyear survival rate were 22.9 months (1.2-179.8 months) and 44%, respectively. In addition, 61 (84%) patients treated with > 40Gy had a survival advantage (median OS 23.7 vs. 17.3 months, p= 0.026), as had patients with 4 months minimum of systemic treatment (median OS 27.5 vs. 14.3 months, p= 0.0004).CRT with total doses > 40Gy after induction chemotherapy leads to improved OS in patients with nonmetastatic pancreatic cancer.
Keywords
SURGERY, Overall survival, ADJUVANT CHEMOTHERAPY, Pancreatic cancer, Retrospective analysis